NCT06342648

Brief Summary

Renal colic is a serious and excruciatingly painful condition that frequently presents itself in the emergency department. In this trial, patients with renal colic who have received intramuscular diclofenac sodium injection or intracutaneous sterile water injection will have their Visual Analogue Scale (VAS) measured and compared.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
570

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 19, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 2, 2024

Completed
29 days until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

April 2, 2024

Status Verified

March 1, 2024

Enrollment Period

6 months

First QC Date

March 19, 2024

Last Update Submit

March 28, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale (VAS)

    Comparing the Visual Analogue Scale (VAS) between patients who had intramuscular diclofenac sodium injection and intracutaneous sterile water injection for the treatment of renal colic. One of the pain rating instruments that Hayes and Patterson used for the first time was the Visual Analogue Scale (VAS), introduced in 1921. A straight line represents the visual analog scale for pain, with zero representing no pain and ten representing the worst possible pain. A patient indicates on the line the location of the point that corresponds to their level of pain.

    For 45 minutes, the VAS will be measured three times, at 15, 30, and 45 minutes of the procedure.

Study Arms (2)

Intracutaneous sterile water injection (ISWI)

ACTIVE COMPARATOR

Sterile water will be intramuscularly injected in the intracutaneous sterile water injection (ISWI) group (Group I) in a plane parallel to the posterior midline, adhering to a predetermined injection pattern from the level of the iliac crest to the last rib.

Drug: Sterile Water Injection

Intramuscular diclofenac sodium injection (DIC)

ACTIVE COMPARATOR

Diclofenac sodium injection intramuscularly (Group II): Diclofenac sodium injection intramuscularly (75 mg) will be given to 285 patients in total.

Drug: Diclofenac Sodium injection

Interventions

Injection of intracutaneous sterile water

Intracutaneous sterile water injection (ISWI)

Injection of intramuscular diclofenac sodium

Intramuscular diclofenac sodium injection (DIC)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients between the ages of 18 and 65.
  • Patients with renal colic at the emergency department of the 30 June Center for Urology and Nephrology, Ismailia, Egypt.

You may not qualify if:

  • Cardiovascular diseases.
  • Renal, and hepatic dysfunction.
  • Hypersensitivity to any of the used drugs.
  • Addiction or chronic use of opioids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Renal Colic

Interventions

Diclofenac

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Central Study Contacts

Abdelrhman Alshawadfy, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor Suez Canal University Faculty of Medicine

Study Record Dates

First Submitted

March 19, 2024

First Posted

April 2, 2024

Study Start

May 1, 2024

Primary Completion

October 30, 2024

Study Completion

December 30, 2024

Last Updated

April 2, 2024

Record last verified: 2024-03